Table 1.

Characteristics of Persons, Vaccines, and Adverse Events Among all MenB-FHbp Reports (n = 2106)

Characteristic	No.	%a
Age group, y
≤9	8	0.4
10–15	142	7
16–18	1039	49
19–25	302	14
≥26	33	1.6
Unknown	582	28
Sex
Female	1149	55
Male	723	34
Unknown	234	11
Persons with risk factors for MenB diseaseb
Complement component deficiencies	1	0.05
Receiving eculizumab	0	0
Anatomic or functional asplenia	8	0.4
Sickle cell disease	1	0.05
Microbiologist	1	0.05
MenB disease outbreak setting	10	0.5
Dose number in MenB-FHbp series
1	1034	49
2	241	11
3	36	2
4 c	2	0.1
Unknown	793	38
Other vaccines on same dayd,e
Any	788	37
MenACWY	447	21
HPV	288	14
Influenza	139	7
Hepatitis A	73	3
Tdap	60	3
Adverse event onset, days postvaccination
0 f	854	41
1	327	16
≥2	143	7
Unknown	782	37
Serious reportb,d	44	2
Hospitalization	42	2
Prolongation of existing hospitalization	0	0
Life-threatening illness	3	0.1
Disability or permanent damage	0	0
Death	0	0
Congenital anomaly or birth defect	0	0
Reporter
Manufacturer	1040	49
Health care professional	768	36
Patient or parent/guardian	111	5
Other or unknown	187	9

Abbreviations: HPV, human papillomavirus; MenACWY, meningococcal serogroups A, C, W, and Y; MenB, meningococcal serogroup B; Tdap, tetanus-diphtheria-acellular pertussis.

^aPercentages may not add up to 100% due to rounding.

^bThis characteristic was confirmed by manual review of reports.

^cMenB-FHbp is approved as either a 2- or 3-dose series; the reason for the fourth dose in 1 report was because the third dose had been given too soon, and the reason was not stated in the other report.

^dCategories are not mutually exclusive.

^eOnly the most common simultaneously received vaccines are shown.

^fThe day of vaccination is referred to as day 0.